Oral Delivery of siRNA Using Fluorinated, Small‐Sized Nanocapsules toward Anti‐Inflammation Treatment
Authors:
- 29 January 2023
- journal article
- research article
- Published by Wiley in Advanced Materials
- Vol. 35 (11) , e2206821
Abstract
Oral delivery of small interfering RNA (siRNA) provides a promising paradigm for treating diseases that require regular injections. However, the multiple gastrointestinal (GI) and systemic barriers often lead to inefficient oral absorption and low bioavailability of siRNA. Technologies that can overcome these barriers are still lacking, which hinders the clinical potential of orally delivered siRNA. Herein, small‐sized, fluorinated nanocapsules (F‐NCs) are developed to mediate efficient oral delivery of tumor necrosis factor α (TNF‐α) siRNA for anti‐inflammation treatment. The NCs possess a disulfide‐cross‐linked shell structure, thus featuring robust stability in the GI tract. Because of their small size (≈30 nm) and fluorocarbon‐assisted repelling of mucin adsorption, the best‐performing F3‐NCs show excellent mucus penetration and intestinal transport capabilities without impairing the intestinal tight junction, conferring the oral bioavailability of 20.4% in relative to intravenous injection. The disulfide cross‐linker can be cleaved inside target cells, causing NCs dissociation and siRNA release to potentiate the TNF‐α silencing efficiency. In murine models of acute and chronic inflammation, orally delivered F3‐NCs provoke efficient TNF‐α silencing and pronounced anti‐inflammatory efficacies. This study therefore provides a transformative strategy for oral siRNA delivery, and will render promising utilities for anti‐inflammation treatment.Keywords
Funding Information
- National Natural Science Foundation of China (52273144, 52033006, 82241008)
This publication has 61 references indexed in Scilit:
- Mechanism of oral tolerance induction to therapeutic proteinsAdvanced Drug Delivery Reviews, 2013
- Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tractAdvanced Drug Delivery Reviews, 2013
- Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriersAdvanced Drug Delivery Reviews, 2012
- Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel diseaseJournal of Controlled Release, 2011
- An Aptamer-siRNA Chimera Suppresses HIV-1 Viral Loads and Protects from Helper CD4 + T Cell Decline in Humanized MiceScience Translational Medicine, 2011
- Orally delivered thioketal nanoparticles loaded with TNF-α–siRNA target inflammation and inhibit gene expression in the intestinesNature Materials, 2010
- Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammationNature, 2009
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Oral gene delivery: Strategies to improve stability of pDNA towards intestinal digestionJournal of Drug Targeting, 2006
- Tumor Necrosis Factor-α Mediates Pancreatitis Responses in Acinar Cells via Protein Kinase C and Proline-Rich Tyrosine Kinase 2Gastroenterology, 2005